IQVIA Holdings Inc. (IQV) has encountered drastic movements recently.
Morgan Stanley and
Truist Securities lowered their price targets yet still maintain a positive rating.
AMG National Trust Bank and
NEOS Investment Management also increased their IQV positions. However,
Vanguard Group,
Running Oak Capital, and
Federated Hermes reduced their stakes in IQV.
IQVIA's EPS surged to US$3.02, causing margin concerns. A closer look at IQVIA's impressive ROE reveals a 20% rate. However, some argue that a 3.6% earnings growth over three years hasn't been enough for positive returns for shareholders. IQVIA also staged at the
Citi 2026 MedTech.
DCRI Collaboration and 2026 growth guidance caused reassessment of the company's valuation. Notably, IQVIA reported record free cash flow and strong Q4 2025 earnings. Despite a 22% gain in share price, asking whether it's time to reassess IQVIA. IQVIA and Duke's Partnership emphasized on obesity focus but it didn't prevent the share weakness. Getting profit margins decline,
IQVIA becomes cautious despite revenue beat and AI strategy emphasis.
Iqvia Holdings IQV News Analytics from Fri, 11 Jul 2025 07:00:00 GMT to Sat, 21 Feb 2026 15:39:09 GMT -
Rating -4
